Ironwood Pharmaceuticals, Inc.
IRWD
$1.45
-$0.09-5.84%
| Weiss Ratings | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.47 | |||
| Price History | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.33% | |||
| 30-Day Total Return | -30.79% | |||
| 60-Day Total Return | -58.92% | |||
| 90-Day Total Return | -65.39% | |||
| Year to Date Total Return | -66.51% | |||
| 1-Year Total Return | -82.96% | |||
| 2-Year Total Return | -86.11% | |||
| 3-Year Total Return | -88.39% | |||
| 5-Year Total Return | -83.10% | |||
| 52-Week High % Change | -83.32% | |||
| 52-Week Low % Change | 14.93% | |||
| Price | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.23 | |||
| 52-Week Low Price | $1.34 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 246.44M | |||
| Enterprise Value | 757.37M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -99.62% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.65 | |||
| Price/Book (Q) | -0.79 | |||
| Enterprise Value/Revenue (TTM) | 2.00 | |||
| Price | $1.45 | |||
| Enterprise Value/EBITDA (TTM) | 7.74 | |||
| Enterprise Value/EBIT | 7.91 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 160.23M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 621 7722 | |||
| Address | 100 Summer Street Boston, MA 02110 | |||
| Website | www.ironwoodpharma.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 25.30% | |||
| Profit Margin | -0.65% | |||
| Management Effectiveness | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 13.10% | |||
| Return on Equity | -- | |||
| Income Statement | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 378.42M | |||
| Total Revenue (TTM) | 378.42M | |||
| Revenue Per Share | $2.36 | |||
| Gross Profit (TTM) | 253.01M | |||
| EBITDA (TTM) | 97.80M | |||
| EBIT (TTM) | 95.76M | |||
| Net Income (TTM) | -2.46M | |||
| Net Income Avl. to Common (TTM) | -2.46M | |||
| Total Revenue Growth (Q YOY) | -19.47% | |||
| Earnings Growth (Q YOY) | -73.86% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | -77.27% | |||
| Balance Sheet | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 88.21M | |||
| Cash Per Share (Q) | $0.55 | |||
| Total Current Assets (Q) | 178.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -311.33M | |||
| Current Ratio (Q) | 3.617 | |||
| Book Value Per Share (Q) | -$1.95 | |||
| Total Assets (Q) | 389.52M | |||
| Total Current Liabilities (Q) | 49.38M | |||
| Total Debt (Q) | 614.87M | |||
| Total Liabilities (Q) | 700.85M | |||
| Total Common Equity (Q) | -311.33M | |||
| Cash Flow | IRWD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.33M | |||
| Cash from Financing (TTM) | -142.99M | |||
| Net Change in Cash (TTM) | -23.25M | |||
| Levered Free Cash Flow (TTM) | 96.30M | |||
| Cash from Operations (TTM) | 124.17M | |||
